Search results
Sep 9, 2020 · Andrew Hirsch, former CEO of Bind Therapeutics, is now leading C4 Therapeutics, a biotech developing protein degraders for various diseases. C4 has collaborations with Roche, Calico and Biogen, and raised $150 million in series B funding.
Sep 8, 2020 · C4 Therapeutics, a biopharmaceutical company developing novel protein degraders for various diseases, announced the hiring of Andrew Hirsch as its new chief executive officer. Mr. Hirsch has over 20 years of experience in the biotechnology industry and was previously CFO and head of corporate development at Agios Pharmaceuticals.
Andrew Hirsch. Editor. Producer. Editorial Department. IMDbPro Starmeter See rank. Andrew Hirsch is known for Danger Force (2020), Henry Danger (2014) and Danger Goes Digital (2021). Add photos, demo reels. Add to list. More at IMDbPro.
- Editor, Producer, Editorial Department
- Andrew Hirsch
Sep 11, 2020 · Andrew Hirsch is wasting no time at his new role running C4 Therapeutics, and, just days after getting the top job, the biotech is gunning for an initial public offering.
Andrew Hirsch - Doctor of Osteopathic Medicine - Horizon Family Medical Group. +1-800-859-0085. patient.concerns@hfmg.net. About us. Quality & Performance. Careers. Contact. Providers Specialties Locations Patient Resources. Pay your bill.
Oct 2, 2020 · Andrew Hirsch, C4 Therapeutics CEO. October 2, 2020 07:14 AM EDT Updated 10:51 AM. People. Financing. R&D. C4's Andrew Hirsch blows up IPO to $182M, while oncolytic virus upstart nabs $87M ...
Sep 9, 2020 · Four years after Andrew Hirsch tied the last loose end on Bind’s bankruptcy package and shipped to Agios as its CFO, he is back at the helm. After the market closed on Tuesday, we learned that ...
